News 25.09.17

NTRC announces approval of key TTK kinase inhibitor patent

NTRC today announced that the USPTO has granted patent protection for a key patent for its TTK kinase inhibitor programme.

Read more
News 14.09.17

Start-up Talent Transmitter opent zijn deuren op het Pivot Park in Oss

Per 18 september vestigt Talent Transmitter zich op het Pivot Park in Oss.

Read more
News 13.09.17

New at Pivot Park – GenTac

GenTac, joining the Pivot Park community in September, provides the tactical and strategic tools of transnational communications to industry, institutions, agencies, publications and nonprofit organizations worldwide.

Read more
News 11.09.17

Step closer to Q-fever vaccine

The development of a new Q-fever vaccine is a little closer to realisation. InnatOss is developing this Q-fever vaccine.

Read more
News 05.09.17

Ceres InnatOss to Launch the Nanotrap® Lyme Antigen Test in the EU

Ceres and Innatoss announced today a partnership that will deliver the Nanotrap® Lyme Antigen Test in the EU.

Read more
News 31.07.17

Genomic drug sensitivity biomarker for TTK inhibitors published in Molecular Cancer Therapeutics

In a new publication, NTRC scientists propose mutations in the cancer hot spot region of the β-catenin gene (CTNNB1) as prognostic drug sensitivity biomarkers for TTK inhibitors.

Read more
News 03.07.17

New at Pivot Park – Atro Medical

ATRO Medical is focusing their R&D activities on the meniscus prothesis Trammpolin™.

Read more
News 27.06.17

NTRC expands Oncolines™ cell line panel to 102 cell lines

NTRC has launched an expansion of its Oncolines™ cancer cell line panel, from 66 to 102 cell lines.

Read more
News 07.06.17

Successful first-in-human study exploiting a unique scalable Natural Killer-cell product

We report the first-in-human study exploiting a unique scalable NK-cell product generated ex vivo from CD34+ hematopoietic stem and progenitor cells (HSPC) from partially HLA-matched umbilical cord blood units.

Read more